Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Keros Therapeutics (KROS) EBT (2019 - 2025)

Keros Therapeutics' EBT history spans 7 years, with the latest figure at -$25.0 million for Q4 2025.

  • For Q4 2025, EBT rose 45.38% year-over-year to -$25.0 million; the TTM value through Dec 2025 reached $91.9 million, up 149.13%, while the annual FY2025 figure was $91.9 million, 149.13% up from the prior year.
  • EBT reached -$25.0 million in Q4 2025 per KROS's latest filing, down from -$8.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $158.5 million in Q1 2025 to a low of -$53.0 million in Q3 2024.
  • Average EBT over 5 years is -$21.3 million, with a median of -$28.5 million recorded in 2022.
  • Peak YoY movement for EBT: crashed 501.46% in 2022, then soared 467.62% in 2025.
  • A 5-year view of EBT shows it stood at -$4.9 million in 2021, then plummeted by 501.46% to -$29.7 million in 2022, then crashed by 56.32% to -$46.5 million in 2023, then grew by 1.57% to -$45.7 million in 2024, then surged by 45.38% to -$25.0 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's EBT are -$25.0 million (Q4 2025), -$8.7 million (Q3 2025), and -$32.9 million (Q2 2025).